M&A Deal Summary

SPIE Acquires Numac

On January 1, 2015, SPIE acquired engineering company Numac from GIMV

Acquisition Highlights
  • This is SPIE’s 1st transaction in the Engineering sector.
  • This is SPIE’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 2015-01-01
Target Numac
Sector Engineering
Buyer(s) SPIE
Sellers(s) GIMV
Deal Type Add-on Acquisition

Target

Numac

Venray, Netherlands
Numac is specialized in machinery maintenance, process optimization, industrial automation and trading in technical equipment. Numac was founded in 2007 and is based in Venray, Netherlands.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

SPIE

Cergy-Pontoise, France

Category Company
Founded 1900
Sector Construction
Employees52,002
Revenue 9.9B EUR (2024)
DESCRIPTION

SPIE provides multi-technical contracting services and offers electrical, heating, ventilation, air conditioning servicing, and mechanical engineering to end markets. SPIE was founded in 1900 and is based in Cergy-Pontoise, France.


DEAL STATS #
Overall 3 of 24
Sector: Engineering M&A 1 of 4
Type: Add-on Acquisition M&A Deals 2 of 23
Country: Netherlands M&A 1 of 4
Year: 2015 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-05 Connectis AG & Softix AG

Switzerland

Connectis AG & Softix AG is a provider of unified communication and collaboration (UCC) technologies in Switzerland and internationally and Softix AG provides information and communication technology servics. connectis AG is based in Emmenbrücke, Switzerland and Softix AG is based in Zurich, Switzerland.

Buy Fr.48M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-01 AGIS Fire & Security

Warsaw, Poland

AGIS Fire & Security distributes electronic security and fire protection solutions in Poland, Greece, Finland, and Hungary.

Buy -

Seller(S) 1

SELLER

GIMV

Antwerp, Belgium

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1980
PE ASSETS 2.0B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.


DEAL STATS #
Overall 58 of 111
Sector: Engineering M&A 1 of 1
Type: Add-on Acquisition M&A Deals 27 of 58
Country: Netherlands M&A 15 of 29
Year: 2015 M&A 3 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-01 Easyvoyage

Paris, France

Easyvoyage is a French information and comparison site on travelling . Easyvoyage with a group of web sites combine comparison engines with several filters (flights, all-in, hotels,…), and extensive, mainly proprietary, content provided by about 20 in-house journalists. Easyvoyage forms a vital link between internet users and online shops (travel agencies, tour operators,…). Easyvoyage was founded in 2000 and is based in Paris, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-13 ActoGeniX NV

Zwijnaarde, Belgium

ActoGenix develops therapies, based on its patented TopAct™ technology platform, which address major diseases requiring intensive medical care, including gastrointestinal problems, auto-immunity diseases, allergies and metabolic disorders. TopAct™ uses micro-organisms for the oral administration of proteins. ActoGeniX’s first product – for treating Crohn’s disease - has already been successfully tested on patients.

Sell $60M